A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Financial Summary
| Share Statistics | TRAW | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6.8 | $579.1 | 5% |
|
| Shares Out (Mil) | 10.6 | 43.0 | 21% |
|
| Institutional Ownership | 84.2% | 84.3% | 52% |
|
| Float (Mil) | 11.7 | 46.8 | 21% |
|
| Beta | 1.47 | 0.62 | 82% |
|
| Avg Daily Volume (000s) | 125 | 285 | 38% |
|
| Price Change (52-week) |
(70.0%) | 63.8% | 9% |
|
| Growth | TRAW | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 69.5% | 6.7% | 97% |
|
| Net Income (5yr) | 18.8% | (1.4%) | 71% |
|
| EPS (5yr) | 15.0% | 14.9% | 56 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 23.2% | (14.9%) | 82% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.450) | ($1.820) | ($1.980) | |
| Month Ago EPS | ($0.450) | ($1.820) | ($1.980) | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($0.590) | ($2.930) | ($3.090) | |
| Year/Year Chg | (15.9%) | (318.2%) | (167.1%) | |
| Financials | TRAW | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3 | $272 | 4% |
|
| Net Income (TTM) (Mil) | ($19) | ($11) | 24% |
|
| EPS (TTM) | ($1.521) | ($0.500) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($15) | ($6) | 16% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $7 | 0% |
|
| Enterprise Value (Q1) (Mil) | $19 | $522 | 11% |
|
| Valuation | TRAW | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.73 | na |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | TRAW | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 65.9% | 96% |
|
| Net Margin | (710.8%) | 0.7% | 1% |
|
| ROA | (142.7%) | (24.6%) | 3% |
|
| ROE | na | (19.7%) | na |
|
| Liabilities to Assets | 165.1% | 35.5% | 98% |
|
| F-Score | 3 | 3 | 19% |
|
Traws Pharma, Inc. did not pass any screens on 7/31/2026.
